The race in psychedelic medicine has focused almost entirely on the molecule. Which compound wins approval first? Which trial reads out next? These are fair questions. But they skip a harder one that decides whether any of this reaches the people who need it: once these medicines are approved, who is actually prepared to deliver them safely?
That is the missing link in psychedelic medicine. The bottleneck is not the drug. It is the psychedelic medicine infrastructure that surrounds every dose: the screening, the trained clinicians, the monitored setting, and the preparation and integration work that turns a chemical experience into lasting change. A promising molecule without that structure around it is a risk, not a treatment. At Nushama, we have spent years building that infrastructure, and we believe the field’s next chapter depends on it.
The molecule was never the hard part
The pharmacology of psychedelic medicine is remarkable, but it is arguably the most solved part of the problem. The harder work is delivery: doing it safely, consistently, and for enough people to matter.
The 2024 FDA decision on MDMA-assisted therapy made this plain. On August 9, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Lykos Therapeutics’ MDMA for post-traumatic stress disorder (PTSD) and asked the company to run another phase 3 trial, according to law firm Holland & Knight’s analysis of the decision. Some of the questions were about trial design and data. But a deeper worry ran underneath the review. As one account of the advisory committee’s reasoning put it, panelists “expressed fear that the current infrastructure could not ensure patient safety at scale,” according to an analysis in The Clinical Trial Vanguard.
Read that again. Even reviewers who found the science promising hesitated because the system around the medicine was not ready. The drug was not the sticking point. Everything around it was.
What “everything around it” actually means
Psychedelic therapy is not a pill you take and forget. The medicine opens a window; what happens before, during, and after decides whether that window leads anywhere. Delivering it well takes an integrated system with several parts working together.
- Medical and psychiatric screening. A thorough intake identifies who is a good candidate and who is not, reviews current medications, and flags contraindications before any dose is given.
- Precise, supervised dosing. The route of administration and the ability to adjust in real time shape both safety and the experience itself.
- A prepared set and setting. The physical space, the mindset a member brings, and the guidance available during the session all influence what unfolds.
- Preparation and integration. Sessions before the journey build trust and set intentions. Sessions afterward help translate insight into changed behavior.
- Trained people. Clinicians, nurses, and integration coaches who understand both the medicine and the vulnerability it creates.
Remove any one of these and you are left with dosing, not care. This is the distinction the field keeps glossing over when it talks about the “next breakthrough.”
Trained people are the real bottleneck
The scarcest resource in psychedelic medicine is not the compound. It is people who know how to hold the experience.
Psychedelic-assisted therapy is unusually labor-intensive. A full treatment protocol in current clinical trials can require more than 42 hours of therapist involvement per person, often delivered by a two-clinician team, according to Prohibition Partners’ Psychedelics as Medicine report. That model does not scale by adding more vials. It scales only by training more skilled clinicians, which takes years.
Meanwhile, the wider mental health workforce is already stretched thin. Researchers writing in Frontiers in Psychiatry in 2023 noted that, according to the Substance Abuse and Mental Health Services Administration, the field faced a projected shortage of 31,000 mental health practitioners. New psychedelic therapies will arrive into a system that is already short-staffed. Approval alone will not create the clinicians needed to deliver these treatments responsibly.
This is why we treat clinical training and protocol as core to the work, not an afterthought. You can read more about what makes our approach different.
Why the delivery method matters more than people think
How a medicine reaches the body is part of the infrastructure, not a footnote. At Nushama, we administer ketamine through an intravenous (IV) line rather than as a lozenge or at-home spray, and the reason is control.
With an IV, a clinician can adjust the infusion rate in real time or stop the session within minutes if a member feels uncomfortable, blood pressure rises, or dissociation (a temporary altered state in which a person may feel detached from their body or surroundings) becomes too intense. At-home and intranasal options remove that control. Once a lozenge is swallowed, absorption continues no matter how the person responds, with no clinician on hand to intervene.
We are not saying other routes have no place. We are saying that when a substance changes consciousness, someone trained should be in the room, able to respond. Precision and supervision are what make the experience both safer and more useful. For a closer look at the trade-offs, see our comparison of IV and intramuscular ketamine.
Preparation and integration are where change sticks
The medicine is a catalyst, not a cure. What a member does in the days around the journey often matters as much as the dose.
Our protocol runs in three phases. In preparation, a member meets with a licensed clinician or integration coach to build a therapeutic alliance, discuss their history, and set intentions. During the journey, the set and setting are deliberate: a private room, an eye mask, curated music, and a guide present at the start and end of the session. In integration, the member works to carry insight into daily life while the brain’s window for change is still open.
Skip the integration step and you let that window close without support. That is the difference between a memorable afternoon and a lasting shift. We have written more about why integration does so much of the heavy lifting.
The evidence for doing it this way
The case for full-container care is not only philosophical. A 2025 real-world study, “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm” by Henry A. MacConnel, Mitch Earleywine, and Steven Radowitz, reported meaningful and durable symptom reduction for people living with treatment-resistant PTSD when IV ketamine was delivered inside a structured psychedelic paradigm rather than as a standalone infusion.
The detail worth sitting with is the phrase “psychedelic paradigm.” The reductions were observed not simply because ketamine was given, but because it was given within a supportive container of preparation, setting, and integration. The infrastructure is not a nice-to-have around the medicine. It may be part of why the medicine works. You can read more about how ketamine may support people with PTSD and trauma.
Access is infrastructure too
Even excellent care does little good if the people who need it most cannot reach it. Cost and stigma keep many people away from treatments that might help them.
That is why we count access as part of the infrastructure we are building, not a marketing add-on. Community programming, scholarship support for those who face financial barriers, and clear, plain-language guidance on what to expect all lower the threshold to care. Environment and community amplify healing; treating access as an afterthought quietly undoes the rest of the work.
What this means for the field
The next few years will bring more approvals, more compounds, and more headlines about breakthroughs. That progress is genuine and worth celebrating. But approval is a starting line, not a finish.
When the next medicine clears the FDA, the question will not be whether the molecule works in a trial. It will be whether clinics can screen the right candidates, dose them safely, guide them through the experience, and support the integration that makes change durable. The brands ready to answer that will be the ones that built the container years earlier, while everyone else was still watching the molecule.
We chose to build the container first. For a fuller picture of how a journey unfolds from consult to integration, see our complete guide to psychedelic therapy or our overview of our practices for safe psychedelic care.
FAQs
What is the biggest barrier to scaling psychedelic therapy?
The main barrier is not the availability of the medicines but the clinical infrastructure needed to deliver them safely. That includes trained clinicians, medical screening, supervised dosing, and structured preparation and integration. The mental health workforce is already short-staffed, and psychedelic-assisted therapy is labor-intensive, so training enough skilled providers is likely the hardest constraint to solve.
Why does Nushama use IV ketamine instead of at-home options?
An intravenous line gives clinicians real-time control. They can adjust the dose or stop a session within minutes if a member becomes uncomfortable or their vital signs change. At-home lozenges and sprays remove that ability, since absorption continues regardless of how the person responds and no clinician is present to intervene. For a controlled substance that alters consciousness, medical supervision supports both safety and results.
What are preparation and integration in ketamine therapy?
Preparation is the work done before a session, where a member meets with a clinician or integration coach to build trust, review their history, and set intentions. Integration is the work afterward, translating the insights from the experience into lasting changes in daily life. Both surround the medicine itself and are considered essential to durable results rather than optional extras.
Does the setting really affect how ketamine therapy works?
Emerging evidence suggests it can. A 2025 real-world study on IV ketamine for treatment-resistant PTSD reported meaningful, sustained symptom reduction when the medicine was delivered within a structured psychedelic paradigm that included preparation, a supportive setting, and integration, rather than as a standalone infusion. The environment and support around the dose appear to be part of why the treatment helps.
Is psychedelic-assisted therapy medically supervised at Nushama?
Yes. Every member begins with a full medical and psychiatric intake to confirm the treatment is appropriate and to review any contraindications. Dosing is handled by licensed physicians, sessions are monitored by clinical staff, and preparation and integration support is provided throughout. This medically supervised model is central to how care is delivered.
Curious whether this approach is right for you or someone you love? Speak with our care team to talk through your history, your questions, and what a supported path might look like.